Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Pant, ShubhamShubhamPantSchuler, MartinMartinSchulerIyer, GopaGopaIyerWitt, OlafOlafWittDoi, ToshihikoToshihikoDoiQin, ShukuiShukuiQinTabernero, JosepJosepTaberneroReardon, David ADavid AReardonMassard, ChristopheChristopheMassardMinchom, AnnaAnnaMinchomLugowska, IwonaIwonaLugowskaCarranza, OmarOmarCarranzaArnold, DirkDirkArnoldGutierrez, MartinMartinGutierrezWinter, HelenHelenWinterStuyckens, KimKimStuyckensCrow, LaurenLaurenCrowNajmi, SaltanatSaltanatNajmiHammond, ConstanceConstanceHammondThomas, ShibuShibuThomasSantiago-Walker, AdemiAdemiSantiago-WalkerTriantos, SpyrosSpyrosTriantosSweiti, HusseinHusseinSweitiLoriot, YohannYohannLoriotCHIH-HUNG HSU2024-01-042024-01-042023-0814702045https://scholars.lib.ntu.edu.tw/handle/123456789/638188FGFR alterations are reported across various malignancies and might act as oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine kinase inhibitor with activity in FGFR-altered advanced urothelial carcinoma. We aimed to evaluate the safety and activity of erdafitinib in previously treated patients with FGFR-altered advanced solid tumours.en[SDGs]SDG3Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyjournal article10.1016/S1470-2045(23)00275-9375412732-s2.0-85166598807https://api.elsevier.com/content/abstract/scopus_id/85166598807